[64Cu]XYIMSR-06: A dual-motif CAIX ligand for PET imaging of clear cell renal cell carcinoma

// Il Minn 1 , Soo Min Koo 1 , Hye Soo Lee 1 , Mary Brummet 1 , Steven P. Rowe 1 , Michael A. Gorin 2 , Polina Sysa-Shah 1 , William D. Lewis 1 , Hye-Hyun Ahn 1 , Yuchuan Wang 1 , Sangeeta Ray Banerjee 1 , Ronnie C. Mease 1 , Sridhar Nimmagadda 1 , Mohamad E. Allaf 2 , Martin G. Pomper 1 , Xing Yang 1 1 Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA 2 The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD, USA Correspondence to: Martin G. Pomper, email: mpomper@jhmi.edu Xing Yang, email: xyang45@jhmi.edu Keywords: carbonic anhydrase IX, positron emission tomography, molecular imaging, renal cell carcinoma, copper-64 Received: February 25, 2016     Accepted: June 09, 2016     Published: July 14, 2016 ABSTRACT Carbonic anhydrase IX (CAIX) is a cell surface enzyme that is over-expressed in approximately 95% of cases of clear cell renal cell carcinoma (ccRCC), the most common renal cancer. We synthesized and performed in vitro and in vivo evaluation of a dual-motif ligand, [ 64 Cu]XYIMSR-06, for imaging CAIX expression on ccRCC tumors using positron emission tomography (PET). [ 64 Cu]XYIMSR-06 was generated in yields of 51.0 ± 4.5% (n=5) and specific activities of 4.1 – 8.9 GBq/μmol (110-240 Ci/mmol). Tumor was visualized on PET images by 1 h post-injection with high tumor-to-background levels (>100 tumor-to-blood and -muscle) achieved within 24 h. Biodistribution studies demonstrated a maximum tumor uptake of 19.3% injected dose per gram of radioactivity at 4 h. Tumor-to-blood, -muscle and -kidney ratios were 129.6 ± 18.8, 84.3 ± 21.0 and 2.1 ± 0.3, respectively, at 8 h post-injection. At 24 h a tumor-to-kidney ratio of 7.1 ± 2.5 was achieved. These results indicate pharmacokinetics superior to those of previously reported imaging agents binding to CAIX. [ 64 Cu]XYIMSR-06 is a new low-molecular-weight PET ligand targeting CAIX, which can image localized and metastatic ccRCC.